Try our mobile app

Published: 2022-03-11 16:54:00 ET
<<<  go to SGEN company page
8-K
false 0001060736 0001060736 2022-03-07 2022-03-07

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 7, 2022

 

 

Seagen Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   0-32405   91-1874389

(State or other jurisdiction

of incorporation or organization)

  

(Commission

File Number)

  

(I.R.S Employer

Identification No.)

 

21823 30th Drive SE
Bothell, Washington 98021
(Address of principal executive offices, including zip code)

(425) 527-4000

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001   SGEN   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02.     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Resignation of Marc E. Lippman, M.D. as Class III Director

On March 7, 2022, Marc E. Lippman, M.D. notified Seagen Inc. (the “Company”) that he will not stand for re-election as a director of the Company at the Company’s 2022 annual meeting of stockholders (the “2022 Annual Meeting”) and that he will resign as a director of the Company effective upon the conclusion of the 2022 Annual Meeting. Dr. Lippman will continue to serve as a director of the Company until the 2022 Annual Meeting. In his notice to the Company with respect to his decision not to stand for re-election and to resign from the Board effective upon the conclusion of the 2022 Annual Meeting, Dr. Lippman indicated that his decision was not the result of any disagreement with the Company, its management, or its board of directors.

 

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

 

104    Cover Page Interactive Data File (formatted in Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SEAGEN INC.
Date: March 11, 2022   By:  

/s/ Jean I. Liu

    Jean I. Liu
    Chief Legal Officer